Aprea Therapeutics, Inc. (APRE)
Develops cancer drugs that exploit genetic weaknesses to kill tumor cells
$0.61-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-63.0%
The outlook
APRE is trading near its 52-week lows, well below both its 50- and 200-day moving averages. Analyst coverage shows an average price target about six times the current price, though the overall sentiment leans bearish. The stock sits at the lower end of its yearly range, reflecting significant pressure despite the optimistic long-term targets.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range5% of the way from its 52-week low to high
Price targetAvg target +601% vs current price
Analyst price target
~12-month · 4 analysts$4.30average target+600.7% vs now
Now $0.61
Low $1.20High $6.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$7.6M
52-wk high
$1.91
52-wk low
$0.55
50-day avg
$0.77
200-day avg
$0.92
Trailing P/E
—